Todd Ranheim

Resilience Therapeutics

Todd has over 20 years of experience building, developing and leading cross functional teams in the execution of innovative analytical and CMC strategies for novel vaccines and biologics. Prior to Resilience, Todd was the head of analytical development at Takeda and responsible for the development of release/stability and clinical assays to support Takeda’s vaccine pipeline which included programs for Dengue, Norovirus, Zika, and sIPV. He supported groups distributed in Singapore, Japan and multiple sites within the US. Before joining Takeda, he spent 4 years as the head of analytical development for Novartis Vaccines in Siena Italy, where he focused primarily on developing the assays enabling the licensure of Bexsero®. Todd’s professional career began in the vaccine division at Merck where he spent 13 years working in various roles. He was responsible for building and managing the analytical development group supporting RotaTeq® and taking the program from research through to commercialization. Todd completed his doctoral training at the Institute for Molecular Virology (St. Louis University Medical School) in the department of Cell and Molecular Biology, where his research focused on the mechanisms adenoviruses use to evade the host immune response. He then completed a postdoctoral appointment at The Scripps Research Institute in the Department of Neurobiology examining N-CAM mediated cell adhesion.